Syndax Forecasts Revuforj Peak Net Revenue Exceeding $2B Ahead of Axatilimab Readouts

Syndax projects that its drug Revuforj will achieve U.S. peak net revenue in excess of $2 billion, as the company approaches key readouts for axatilimab in the fourth quarter.